Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesVivani Medical Inc.

Vivani Medical Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.06 USD -0.03 ( 2.75%)
Last update at 2026-11-03T20:55:00Z
VOLUME
248403
Market Cap
110.95M

Momentum Score

…

Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.04
Low
1.13
High
52 Week Price Range
0.92
Low
1.92
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Vivani Medical Inc. (NASDAQ: VANI) is limited; the company describes itself as a medical technology firm developing clinical solutions for wound care and related diagnostics. Long-term growth may depend on clinical validation, successful commercialization, reimbursement adoption and scaling of its technology, and investors may find exposure to data-driven clinical tools addressing chronic care needs attractive if those milestones are achieved.

Material risks include limited disclosure and operating history, development-stage status requiring additional financing, regulatory and clinical hurdles, and significant execution and market-competition risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.09
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.13M
Debt / Equity
1.20
ROE
-220.41%
Net Debt
2.62M
ROCE
-81.15%
Diluted EPS TTM
-0.36

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -26.61M -23.49M -25.65M -13.89M -12.77M
Net income -26.61M -23.49M -25.65M -6.54M -12.13M
Selling general administrative 9.43M 8.93M 10.00M 7.07M 2.32M
Selling and marketing expenses - - 0.36M - -
Gross profit -0.42M -0.40M -0.36M - 0.00M
Reconciled depreciation 0.42M 0.40M 0.37M 0.38M 0.34M
Ebit -26.61M -23.49M -25.65M -21.24M -13.32M
Ebitda -26.18M -23.09M -25.30M -27.74M -13.62M
Depreciation and amortization 0.42M 0.40M 0.36M -6.50M -0.30M
Operating income -27.56M -24.68M -26.96M -21.24M -13.32M
Other operating expenses 27.56M 24.68M 26.96M 21.24M 13.32M
Interest expense - - - -7.35M 0.55M
Income tax expense - -23.49M - -7.35M -0.64M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 27.13M 24.68M 26.61M 21.24M 13.32M
Cost of revenue 0.42M 0.40M 0.36M - 0.00M
Total other income expense net 0.95M 1.19M 1.31M 7.35M 0.55M
Net income from continuing ops -26.61M -23.49M -26.91M -13.89M -12.77M
Net income applicable to common shares - - - - -8.92M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 39.39M 41.56M 45.80M 51.13M 5.45M
Other current assets 1.01M 1.84M 2.41M 2.45M 0.29M
Total liab 23.66M 23.95M 25.04M 6.82M 2.99M
Total stockholder equity 15.73M 17.61M 20.76M 44.31M 2.46M
Other current liab 3.78M 3.82M 3.46M 4.69M 0.90M
Common stock 0.01M 0.01M 0.01M 109.05M 54.65M
Capital stock 0.01M 0.01M 0.01M 109.05M 54.65M
Retained earnings -148.53M -121.92M -98.44M -72.79M -58.90M
Other assets - - 0.00M - 0.03M
Cash 16.23M 18.35M 20.65M 45.08M 2.18M
Total current liabilities 6.60M 5.99M 5.72M 6.82M 2.09M
Current deferred revenue - - 0.34M - -
Net debt 2.62M 0.96M 0.04M -44.12M -0.37M
Short term debt 1.79M 1.35M 1.38M 0.95M 0.91M
Short long term debt total 18.86M 19.31M 20.70M 0.95M 1.81M
Other stockholder equity 164.22M 139.48M 119.05M 8.01M 6.71M
Property plant equipment - - - - 0.34M
Total current assets 17.90M 20.44M 23.06M 47.53M 2.47M
Net tangible assets - - - - 68.36M
Net receivables 0.65M 0.25M - - -
Accounts payable 1.03M 0.82M 0.54M 1.18M 0.28M
Accumulated other comprehensive income 0.03M 0.05M 0.14M 0.04M -0.38M
Non currrent assets other 0.05M 0.13M 0.05M 1.64M 0.20M
Non current assets total 21.50M 21.12M 22.73M 3.60M 2.98M
Capital lease obligations 18.86M 19.31M 20.70M 0.95M 1.81M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.56M -0.18M -0.34M -0.57M
Change to liabilities - - - - 0.06M
Total cashflows from investing activities -1.17M -0.56M -0.89M - -0.01M
Net borrowings 0.01M 0.43M 0.00M - -2.20M
Total cash from financing activities 23.27M 19.05M 0.13M 63.39M 11.62M
Change to operating activities - - - - -0.48M
Net income -26.61M -23.49M -25.65M -13.89M -12.77M
Change in cash -2.12M -2.30M -24.45M 44.26M 0.10M
Begin period cash flow 19.69M 21.99M 46.44M 2.18M 2.08M
End period cash flow 17.57M 19.69M 21.99M 46.44M 2.18M
Total cash from operating activities -24.32M -20.79M -23.70M -18.79M -10.95M
Issuance of capital stock 23.29M 18.82M 0.13M 0.02M 11.62M
Depreciation 0.42M 0.40M 0.36M 0.38M 0.34M
Other cashflows from investing activities - -13.69M - - -
Change to account receivables -0.40M - - - -
Sale purchase of stock -0.03M - - - -
Other cashflows from financing activities - -18.82M 0.13M 63.37M -0.57M
Change to netincome - - - - 0.08M
Capital expenditures 1.17M 0.56M 0.89M 0.34M 0.57M
Change in working capital 0.23M 0.35M -1.29M 0.34M 0.45M
Stock based compensation 1.48M 1.61M 1.86M 1.30M 1.67M
Other non cash items 0.15M 0.34M 1.02M -6.91M -0.64M
Free cash flow -25.49M -21.34M -24.59M -19.12M -11.52M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
VANI
Vivani Medical Inc.		 -0.03
2.75%		 1.06 - - - 5.99 -3.93
NVO
Novo Nordisk A/S		 -0.24
0.61%		 40.20 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -21.28
3.85%		 531.87 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 12.10
1.26%		 973.36 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Vivani Medical Inc.

Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.

1350 South Loop Road, Alameda, CA, United States, 94502

415 506 8462

https://www.vivani.com

42

Name Title Year Born
Mr. Adam Mendelsohn Ph.D. Co-Founder, Chairman & CEO NA
Mr. Truc Le M.B.A. Chief Operations Officer 1953
Dr. Lisa E. Porter M.D. Chief Medical Officer 1964
Mr. Donald Dwyer M.B.A. Chief Bus. Officer NA
Dr. Kayte Fischer Ph.D. Co-Founder NA
Ms. Brigid Ann Makes Chief Financial Officer 1956
Mr. Adam Mendelsohn Ph.D. Co-Founder, CEO & Director 1982
Mr. Donald Dwyer M.B.A. Chief Business Officer NA
Dr. Adam Mendelsohn Ph.D. Co-Founder, CEO & Director 1982
Mr. Anthony Edward Baldor M.B.A. Chief Financial Officer 1982

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…